– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity ...

– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – SOUTH SAN ...

– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...

LW-231, under development by Shanghai Longwood Biopharmaceuticals Co. Ltd., is a novel bifunctional molecule designed to simultaneously modulate hepatitis B virus (HBV) capsid assembly and activate ...

Researchers from Weifang Medical University and affiliated organizations have published details on the discovery of novel hepatitis B virus (HBV) capsid assembly modulators (CAMs).

New hollow dodecahedral shell demonstrates remarkable stability and potential for functionalization and encapsulating macromolecules. (Nanowerk News) Controlling the topology and structure of ...

RNA viruses are renowned for their elegant structure and finely tuned self‐assembly processes, which are critical both for viral life cycles and for potential applications in nanotechnology and ...

In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...

– In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days of treatment – – Enrollment in final cohort of 400 mg ...

Researchers develop a large dodecahedral structure through the self- assembly of metal ions and peptides, with potential implications in drug delivery systems and molecular transportation. Controlling ...

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 ...